How to transfer my Strattera prescription to

If you’re struggling with ADHD symptoms and wondering whether you can get treatment through telehealth, you’re not alone. Millions of Americans have turned to online platforms for ADHD care, especially since the COVID-19 pandemic reshaped how we access healthcare. The short answer is yes—you can receive ADHD medication through telehealth in most cases. But the details matter, and navigating federal rules, state laws, and medication types can feel overwhelming.

This guide breaks down everything you need to know about getting ADHD medication online in 2025, from understanding which medications are available via telehealth to state-specific regulations that might affect your care.

Understanding ADHD Medications and Telehealth

ADHD medications fall into two main categories: stimulants (like Adderall, Ritalin, and Vyvanse) and non-stimulants (like Strattera, Intuniv, and Kapvay). The type of medication you’re prescribed significantly impacts whether—and how—you can receive it through telehealth.

Non-Stimulant Medications: The Straightforward Option

Non-stimulant ADHD medications, such as Strattera (atomoxetine), are not controlled substances and face no special federal restrictions for telehealth prescribing. This means a licensed provider can evaluate you via video visit, confirm an ADHD diagnosis, and electronically prescribe Strattera or similar medications without requiring an in-person appointment first.

Strattera isn’t habit-forming and carries no potential for abuse, which is why it’s not tracked by the Drug Enforcement Administration (DEA) as a controlled substance. From a regulatory standpoint, prescribing Strattera via telehealth is no different than prescribing blood pressure medication or antibiotics—as long as the provider follows standard medical care practices and is licensed in your state.

Key benefits of non-stimulants for telehealth:

• No federal in-person exam requirement
• Can be prescribed in 90-day supplies for convenience
• Refills available without monthly appointments
• Lower regulatory scrutiny and fewer state restrictions

Stimulant Medications: More Complex but Available

Stimulant medications like Adderall and Vyvanse are Schedule II controlled substances, which means they fall under strict DEA oversight due to their potential for abuse and dependence. Under normal circumstances, the Ryan Haight Act (passed in 2008) requires an in-person medical evaluation before a provider can prescribe controlled substances via telemedicine.

However, during the COVID-19 public health emergency, the DEA temporarily waived this requirement. As of December 2025, this waiver has been extended through December 31, 2025, allowing providers to prescribe Schedule II-V controlled substances via telehealth without a prior in-person exam. The DEA has signaled that a fourth extension for 2026 is under review, though nothing is finalized yet.

This means that right now, you can get stimulant ADHD medications through telehealth in most states—but this flexibility depends on temporary federal rules that could change. Patients and providers should stay informed about potential policy shifts heading into 2026.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Regulations: What You Need to Know

Current DEA Telehealth Rules (Through End of 2025)

The DEA’s ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities’ allows healthcare providers to prescribe controlled substances (including ADHD stimulants) via telehealth without requiring an initial in-person visit. This applies to medications in Schedule II through Schedule V.

What this means for patients:

• You can start ADHD treatment entirely through telehealth
• No need to visit a doctor’s office for your first prescription
• Follow-up appointments can also be conducted virtually
• Your provider must still have proper DEA registration and state licensure

What Happens After December 31, 2025?

The current telehealth flexibilities expire at the end of 2025. While the DEA is expected to either extend these rules again or implement new permanent regulations (possibly including a special telehealth registration system), there’s no guarantee of what the landscape will look like in 2026.

Potential scenarios:

• Another extension: The DEA continues temporary flexibilities into 2026 or beyond
• New permanent framework: New rules might require an in-person visit within a certain timeframe (some proposals suggested within 30 days of starting treatment)
• Return to pre-pandemic rules: In-person exams would be required before any controlled substance prescriptions via telehealth

If you’re currently receiving ADHD treatment through telehealth, your provider will notify you of any changes and help coordinate necessary in-person visits if required.

State-by-State Telehealth Rules for ADHD Treatment

While federal law sets the baseline, state regulations add another layer of requirements that can significantly impact your access to telehealth ADHD care. Here’s what you need to know about key states:

California: Telehealth-Friendly with Expanding Access

California permits telehealth prescribing for both stimulant and non-stimulant ADHD medications. The state doesn’t require an in-person exam for telehealth prescriptions, and a video evaluation satisfies the ‘good faith exam’ standard for establishing a provider-patient relationship.

California highlights:

• No in-person visit required for ADHD medications
• Nurse practitioners have independent prescribing authority
• PDMP checks required for controlled substances every 4 months
• Pending legislation (AB 1503) may further clarify telehealth prescribing rules

New York: Stricter Rules Implemented in 2025

New York took a more cautious approach in May 2025 by implementing a mandatory in-person evaluation requirement for prescribing controlled substances via telehealth. This means if you’re seeking stimulant ADHD medication in New York, you’ll need an initial in-person visit before your provider can prescribe via telehealth.

Important note: This requirement applies only to controlled substances. Non-stimulant medications like Strattera can still be prescribed through telehealth without an in-person visit.

Florida: Psychiatric Exception Allows Telehealth Access

Florida law prohibits telehealth prescribing of Schedule II medications (including ADHD stimulants) unless the medication is prescribed for a psychiatric condition. Since ADHD is classified as a psychiatric disorder, telehealth prescribing of stimulants is permitted under this exception.

Florida requirements:

• Must use video (not phone-only) for controlled substance prescriptions
• PDMP check required before every controlled substance prescription
• Non-stimulants like Strattera have no special restrictions
• Nurse practitioners can prescribe with physician collaboration

Texas: Mental Health-Friendly Telehealth

Texas broadly supports telehealth for mental health and chronic care, including ADHD treatment. However, the state has restrictions on who can prescribe Schedule II medications via telehealth.

Texas specifics:

• Physicians (MDs/DOs) can prescribe stimulants via telehealth for ADHD
• Nurse practitioners and physician assistants can prescribe Schedule II medications only in hospital or hospice settings
• Outside these settings, NPs/PAs are limited to Schedule III-V medications
• No in-person requirement for ADHD telehealth treatment

Alabama: Strict Annual In-Person Requirements

Alabama maintains one of the strictest telehealth policies in the country. After four telehealth visits for the same condition, patients must have an in-person visit within 12 months.

Alabama exceptions:

• Mental health services are exempt from the 12-month rule
• A licensed medical professional can be physically present with the patient during telehealth visits to satisfy requirements
• PDMP checks required for controlled substances

New Hampshire: Recently Expanded Access

New Hampshire significantly loosened its telehealth restrictions in August 2025. The state removed its prior in-person requirement and now only mandates an annual follow-up evaluation (which can be conducted via telehealth) for patients receiving controlled medications.

New Hampshire changes:

• No initial in-person exam required
• Annual follow-up evaluation required for controlled substances
• Nurse practitioners have independent prescribing authority
• PDMP check required before each controlled substance prescription

Who Can Prescribe ADHD Medications via Telehealth?

The type of provider you see can impact your access to certain ADHD medications, especially stimulants.

Physicians (MD/DO)

Licensed physicians can prescribe all ADHD medications—both stimulants and non-stimulants—via telehealth in any state, provided they:

• Hold an active medical license in your state
• Have proper DEA registration for controlled substances
• Follow applicable state telehealth regulations

Nurse Practitioners (NPs)

Nurse practitioner prescribing authority varies significantly by state:

Independent Practice States: Over 20 states (including New York, Illinois, New Hampshire, and California) allow NPs to prescribe Schedule II-V medications independently after meeting experience and training requirements. In these states, NPs can prescribe ADHD stimulants without physician oversight.

Collaborative Practice States: Many states (including Florida, Pennsylvania, and Texas) require NPs to have a collaborative agreement with a physician. While NPs can still prescribe ADHD medications in these states, they must work under physician supervision.

Restricted States: A few states severely limit or prohibit NP prescribing of Schedule II medications. For example:

• Georgia: NPs cannot prescribe Schedule II drugs even with physician delegation
• Texas: NPs can prescribe Schedule II only in hospital or hospice settings

Non-stimulant note: In all states, NPs can prescribe non-stimulant ADHD medications like Strattera with at least a collaborative agreement, making these medications more accessible for patients seeing nurse practitioners.

Physician Assistants (PAs)

Physician assistants generally practice under physician supervision and face similar restrictions to nurse practitioners when prescribing controlled substances. Requirements vary by state, but PAs can typically prescribe non-stimulant ADHD medications with proper supervision and delegation agreements.

The Telehealth ADHD Evaluation Process

Getting ADHD medication through telehealth isn’t as simple as filling out an online quiz. Legitimate telehealth providers must follow the same diagnostic criteria and safety protocols as in-person care.

What to Expect During Your Evaluation

Comprehensive intake: You’ll complete detailed questionnaires about your symptoms, medical history, previous treatments, and current medications. Many providers ask about symptoms across multiple settings (work, school, home) to confirm ADHD meets DSM-5 diagnostic criteria.

Video consultation: A licensed provider will conduct a live video evaluation (typically 45-60 minutes for initial visits). They’ll discuss your symptoms, ask about childhood onset, assess functional impairment, and rule out other conditions that might mimic ADHD.

Diagnostic assessment: Providers often use standardized rating scales (like the ASRS or Conners scales) and may request input from family members or review old report cards to confirm symptoms began in childhood.

Treatment planning: If ADHD is diagnosed, your provider will discuss medication options, potential side effects, non-medication strategies, and the importance of follow-up care.

Documentation Requirements

Be prepared to provide:

• Government-issued photo ID
• Insurance information (if applicable)
• Previous medical records or psychological evaluations (if available)
• Contact information for your primary care provider
• Emergency contact information

Red Flags That May Disqualify You

Telehealth providers must prioritize patient safety. You may not be eligible for stimulant medications via telehealth if you have:

• Uncontrolled high blood pressure or serious heart conditions
• History of substance abuse or active addiction
• Severe, untreated mental health conditions (like uncontrolled bipolar disorder)
• Recent requests for early refills or ‘doctor shopping’ behavior
• Refusal to consent to prescription monitoring database checks

In these cases, a provider might recommend an in-person specialist evaluation, prescribe a non-stimulant alternative, or require additional testing before prescribing controlled medications.

Medication Options and What to Expect

Non-Stimulant Medications

Strattera (atomoxetine) is the most commonly prescribed non-stimulant for ADHD. Unlike stimulants that work immediately, Strattera typically takes 4-6 weeks to reach full effectiveness.

Advantages:

• Not a controlled substance (no abuse potential)
• Can be prescribed in 90-day supplies
• Works 24/7 (no ‘wearing off’ effect)
• May help with anxiety symptoms
• Lower risk of sleep problems

Considerations:

• Slower onset of action than stimulants
• May cause nausea initially (usually improves)
• FDA warning for suicidal thoughts in youth (rare but monitored)
• Requires periodic monitoring of blood pressure and heart rate

Other non-stimulant options include Intuniv (guanfacine) and Kapvay (clonidine), which are alpha-2 agonists originally developed for blood pressure. These can be particularly helpful for hyperactivity and impulsivity.

Stimulant Medications

If prescribed stimulants via telehealth, you should know:

• Schedule II status: These medications require monthly prescriptions with no refills (a new prescription is needed each month)
• 30-day supply limit: Federal law restricts stimulant prescriptions to 30 days at a time
• PDMP monitoring: Your provider must check state prescription monitoring databases regularly
• Treatment agreement: Many providers require signed agreements outlining safe use, not sharing medication, and compliance with drug testing if requested

Common stimulants include:

• Amphetamines: Adderall, Vyvanse, Dexedrine
• Methylphenidates: Ritalin, Concerta, Focalin

Working with Klarity Health for ADHD Treatment

At Klarity Health, we’ve designed our telehealth platform to provide comprehensive, safe, and accessible ADHD care while navigating the complex regulatory landscape. Here’s what sets us apart:

Provider Availability

We connect you with board-certified psychiatrists, psychiatric nurse practitioners, and licensed clinicians who specialize in ADHD treatment. Our providers are licensed in your state and have the necessary DEA registrations to prescribe controlled substances where applicable.

Appointment availability: Many patients can schedule appointments within days, not the weeks or months typical of traditional psychiatric care. We offer flexible scheduling, including evening and weekend appointments.

Transparent Pricing

We believe healthcare costs should be clear and predictable. Whether you’re using insurance or paying out-of-pocket, you’ll know the cost upfront—no surprise bills.

Insurance accepted: Klarity Health works with most major insurance plans. We’ll verify your coverage and explain your expected costs before your appointment.

Cash-pay option: If you prefer to pay directly or don’t have insurance that covers telehealth, we offer affordable self-pay rates. Our cash pricing is often comparable to insurance copays at traditional offices.

Comprehensive Care Model

ADHD treatment is more than just medication. Our providers:

• Conduct thorough diagnostic evaluations using evidence-based criteria
• Discuss both medication and non-medication strategies
• Provide ongoing monitoring and dose adjustments
• Can coordinate with your therapist or primary care provider
• Offer medication management appointments as needed (typically monthly for stimulants)

We also encourage patients to consider behavioral therapy, coaching, or counseling alongside medication. While Klarity primarily focuses on medication management, we can provide referrals to therapists who specialize in ADHD.

Safety and Compliance

Your safety is our priority. Klarity providers:

• Check prescription monitoring databases as required by law
• Screen for contraindications and risk factors
• Require regular follow-ups to monitor effectiveness and side effects
• Practice evidence-based prescribing (no ‘pill mill’ practices)
• Maintain strict privacy and HIPAA compliance

Practical Tips for Telehealth ADHD Treatment

Before Your Appointment

1. Prepare your symptom history: Write down specific examples of how ADHD symptoms affect your daily life
2. Gather documentation: Collect any previous ADHD evaluations, report cards, or relevant medical records
3. List current medications: Include all prescriptions, supplements, and over-the-counter drugs
4. Create a quiet space: Ensure you’ll have privacy and a stable internet connection for your video visit
5. Have questions ready: Write down anything you want to discuss with your provider

During Treatment

1. Attend follow-up appointments: Regular monitoring is essential, especially when starting or adjusting medications
2. Track your response: Keep notes on symptom improvement, side effects, and any concerns
3. Communicate openly: Be honest about medication effects, compliance issues, or life changes
4. Don’t adjust doses on your own: Always consult your provider before changing how you take medication
5. Report side effects promptly: Many side effects can be managed with dose adjustments or different medications

Managing Your Prescription

1. Use one pharmacy consistently: This helps pharmacists track your medications and identify potential interactions
2. Request refills on time: For controlled substances, you’ll need a new prescription each month—plan ahead to avoid gaps
3. Store medication securely: Keep medications in a safe place, especially if you have children or roommates
4. Never share your medication: Sharing prescription stimulants is illegal and dangerous
5. Bring your medication bottle to appointments: This helps your provider verify what you’re taking

Common Misconceptions About Online ADHD Treatment

‘Online prescriptions are automatic or too easy to get’

Reality: Legitimate telehealth platforms require the same comprehensive evaluation as in-person care. Providers must follow DSM-5 diagnostic criteria, conduct thorough assessments, and document medical necessity. If a service promises medications after a brief questionnaire with no video consultation, that’s a red flag for an illegitimate operation.

‘Non-stimulants don’t work as well as stimulants’

Reality: While stimulants are considered first-line treatment for many patients, non-stimulants like Strattera can be highly effective, especially for patients who:

• Have a history of substance abuse
• Experience intolerable stimulant side effects
• Have anxiety that worsens with stimulants
• Prefer once-daily dosing with 24-hour coverage
• Can’t use controlled substances due to work restrictions

‘Telehealth doctors can’t prescribe controlled medications’

Reality: Under current federal rules (through end of 2025), licensed providers with DEA registration can prescribe controlled substances via telehealth. Thousands of patients successfully receive ADHD stimulant medications through telehealth platforms. The key is ensuring your provider is properly licensed and follows all applicable regulations.

‘Pharmacies won’t fill telehealth prescriptions’

Reality: Most pharmacies readily fill legitimate telehealth prescriptions. Electronic prescriptions don’t indicate whether your visit was virtual or in-person. However, some pharmacies may ask additional verification questions for controlled substances, which is a normal safety practice—not a rejection of telehealth care.

What’s Next: The Future of ADHD Telehealth

As we look toward 2026 and beyond, several trends are shaping the future of telehealth ADHD treatment:

Regulatory Evolution

DEA rulemaking: The DEA is working on permanent telehealth regulations that may include a special registration system for providers. While details remain unclear, the goal is to create a sustainable framework that balances access with safety.

State modernization: More states are updating their telehealth laws to permanently allow remote prescribing. New Hampshire’s 2025 reforms demonstrate this trend, with other states likely to follow.

Congressional action: Federal lawmakers are considering bills like the TREATS Act to expand telehealth access and create interstate licensing frameworks for tele-psychiatry.

Enhanced Safety Measures

The telehealth industry has responded to scrutiny by implementing stronger safeguards:

• More rigorous diagnostic evaluations
• Mandatory treatment agreements for controlled substances
• Regular drug testing protocols
• Coordination with primary care providers
• Periodic in-person check-ins for high-risk patients

Integrated Care Models

The future of ADHD telehealth will likely include:

• Better integration between medication management and therapy
• Coordinated care with schools and employers
• Digital tools for symptom tracking and medication adherence
• Hybrid models combining telehealth and in-person visits as needed

Taking the Next Step

If you’re struggling with ADHD symptoms—difficulty focusing, chronic disorganization, impulsivity, or hyperactivity—telehealth treatment offers a convenient, effective path to getting help. Whether you’re seeking non-stimulant medications like Strattera or need a comprehensive evaluation to explore all treatment options, platforms like Klarity Health can connect you with qualified providers who understand both ADHD and the evolving telehealth landscape.

Ready to start? The process typically begins with:

1. Completing an online intake form
2. Scheduling a video evaluation with a licensed provider
3. Receiving a personalized treatment plan
4. Getting prescriptions sent electronically to your pharmacy
5. Scheduling follow-up appointments for ongoing care

Remember: While regulations are complex and evolving, legitimate telehealth providers stay current with all requirements to ensure you receive safe, legal, and effective care. Don’t let confusion about regulations prevent you from seeking help—the right provider will navigate these complexities for you.

ADHD is highly treatable, and telehealth has made expert care more accessible than ever. With the right support, you can develop strategies and find treatments that help you thrive.

References

1. FierceHealthcare. ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth, punts final rule.’ November 2024.

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ December 2025.

3. Sheppard Mullin Healthcare Law Blog (National Law Review). ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ August 15, 2025.

4. Center for Connected Health Policy (CCHP). ‘Online Prescribing State Laws & Reimbursement Policies.’ Accessed November-December 2025.

5. Medical News Today. ‘Is Strattera a controlled substance?’ Medically reviewed, January 14, 2025.

Note: This article reflects regulations and policies current as of December 17, 2025. ADHD telehealth laws continue to evolve. Always verify current requirements with your healthcare provider and check for the latest federal and state updates.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment